Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH16176Aexternal-prioritypatent/CH624395A5/de
Application filed by Ciba Geigy AgfiledCriticalCiba Geigy Ag
Publication of PT66036BpublicationCriticalpatent/PT66036B/en
Publication of PT66036A1publicationCriticalpatent/PT66036A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Hydroxybenzodiheterocyclic cpds. of formula (I) as the racemate or antipodes and their acid addition salts are novel cpds: In (I) R1 is opt. substd. lower alkyl which may be branched at the bonding C atom (the preferred substituents are opt. substd. aryl or aryloxy groups). R2 is H or lower alkanoyl; R3 is -R'3-(R"3)n- (Gp. Ia); R'3 is -NR4 or -O-; R4 is H or lower alkyl; R"3 is -CH2- or when R'3 is -NR4 then R3" may be C=O; n = 0 or 1. When n = 1 the gp. (Ia) may be joined to the -CO of the carbamoyl via R'3 or R"3. Lower groups contain 7C atoms pref. =4C atoms. Cpds. (I) are used to treat cardiac arrhythmia, coronary disorders, such as angina pectoris, and hypertension and cardiac stimulants. Some of the cpds. are alpha-adrenergic receptor blockers and act as hypotensives. They are administered orally (e.g. in daily doses of 1-15 mg for a 70 kg adult) or parenterally. A typical prod. is 5-(3-tert-butylamino-2-hydroxy-propoxy)-(1H)(3H)-quinazolin-2,4-d- ione.
PT6603677A1976-01-081977-01-06Process for preparation of etherified hydroxibenzodiheterocyclic compounds
PT66036A1
(en)